Navigation Links
Antibiotic-resistant typhoid likely to spread despite drug control program
Date:12/9/2013

Restricting the use of antibiotics is unlikely to stop the spread of drug resistance in typhoid fever, according to a study funded by the Wellcome Trust and published in the journal eLife.

The findings reveal that antibiotic-resistant strains of Salmonella Typhi bacteria can out-compete drug sensitive strains when grown in the laboratory, even in the absence of antibiotics.

Typhoid fever is transmitted by consuming food or drink that is contaminated with Salmonella Typhi bacteria and the disease is linked to poor sanitation and limited access to clean drinking water. The disease can be treated but there is widespread drug resistance to common antibiotics and resistance to the recommended, more specialised antibiotic therapy for typhoid fever is increasing.

Researchers at the Oxford University Clinical Research Unit, Wellcome Trust Vietnam Research Programme, created twelve laboratory strains of Salmonella Typhi bacteria with one or more genetic mutations that confer resistance to the recommended antibiotic therapy for typhoid fever, fluoroquinolone. Typically, when bacteria develop antibiotic resistance it comes at a cost and when the drug is absent, they are usually weaker and less able to compete for food and resources than strains that are not resistant.

Dr Maciej Boni, a Sir Henry Dale Fellow funded jointly by the Wellcome Trust and Royal Society at the Oxford University Clinical Research Unit in Vietnam, who co-led the study, said: "When we grew different strains of Salmonella Typhi in the lab, we found that half of the antibiotic resistant strains had a growth advantage over their parent strain, even in the absence of antibiotic, enabling them to predominate in the population."

Dr Stephen Baker, also a Sir Henry Dale Fellow in the Oxford University Clinical Research Unit, said: "Currently, the control of typhoid across Asia and Africa relies on treatment with fluoroquinolones but resistance is rising. Withdrawing or restricting the use of this class of antibiotics is one approach to try and combat the spread of resistance. However, the results of this study suggest that we need to think beyond this , as antibiotic resistance will likely continue to rise even if these strategies are implemented."

Dr Jimmy Whitworth, Head of International Activities at the Wellcome Trust, said: "These important findings from researchers in Vietnam are very worrying. If confirmed, one of our main strategies for controlling drug-resistance in typhoid will be ineffective. We will need to concentrate on developing more effective and affordable vaccines, and improving water supplies and sanitation, a Herculean task for low and middle income countries."

There are an estimated 21 million cases of typhoid fever around the world each year. If left untreated, it's estimated that up to one in five with the disease will die and of those who survive, some will have permanent physical or mental disabilities. According to a World Health Organization report, 90% of the world's typhoid deaths occur in Asia and the disease persists mainly in children under five years.

Typhoid infects the gut and bloodstream, causing fever that can reach temperatures of 39-40 C and constipation or diarrhoea. The disease can be associated with other characteristics including, rose-coloured spots on the chest, confusion and perforation of the gut.


'/>"/>

Contact: Jen Middleton
j.middleton@wellcome.ac.uk
44-207-611-7262
Wellcome Trust
Source:Eurekalert

Related biology news :

1. Antibiotic-resistant pathogens persist in antibiotic-free pigs
2. New study shows how copper restricts the spread of global antibiotic-resistant infections
3. Scientists notch a win in war against antibiotic-resistant bacteria
4. Lack of energy an enemy to antibiotic-resistant microbes
5. Researchers track antibiotic-resistant strains of Salmonella from farm to fork
6. Costs for changing pollution criteria in Florida waters likely to exceed EPA estimates
7. Evidence shows that anti-depressants likely do more harm than good, researchers find
8. Nearly one-tenth of hemispheres mammals unlikely to outrun climate change
9. Girls mathematics performance more likely to suffer than boys as a result of mathematics anxiety
10. Research warns Asia unlikely to achieve climate, poverty goals unless womens rights are recognized
11. Southern elephant seals likely detect prey bioluminescence for foraging
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... present at the LEERINK Partners 6th Annual Global Healthcare ... Wednesday, February 15, 2017 at 10 a.m. Eastern Time. ... can be accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast ... Zimmer Biomet,s Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
(Date:2/1/2017)... , February 1, 2017 IDTechEx Research, a ... emerging technology, announces the availability of a new report, Sensors ... Continue Reading ... ... and collaborative robots. Source: IDTechEx Report "Sensors for Robotics: Technologies, Markets ...
Breaking Biology News(10 mins):
(Date:2/16/2017)... 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company ... better treatment for triple negative breast cancer (TNBC), announced today ... program. The YEi Start in ... help entrepreneurs grow their business in France ... companies selected to complete an intensive one week immersion in ...
(Date:2/16/2017)... LOS ANGELES , Feb. 16, 2017 /PRNewswire/ ... CAPR ), a clinical-stage biotechnology company developing first-in-class ... today announced that it has elected to terminate ... to natriuretic peptide receptor agonists, including Cenderitide. ... a strategic move as we prioritize our efforts ...
(Date:2/16/2017)... N.J. , Feb. 16, 2017  Champions Oncology, ... in the development and sale of advanced technology solutions ... oncology drugs, today announced the addition of new cohorts ... These new models will expand Champions, product line ... head and neck cancer, AML, and non-small cell lung ...
(Date:2/16/2017)... LAFAYETTE, Indiana (PRWEB) , ... ... ... division of Albany Molecular Research Inc. has further extended its industry leading ... This service offers state-of-the-art cGMP techniques and methods for the ...
Breaking Biology Technology: